New chemical Entity Registered ( )
|
|
- Wilfrid Wilcox
- 6 years ago
- Views:
Transcription
1 N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib mina Janssen cilag 3 19/7/2005 Avastin Vial 100 Bevacizumab roche 4 Aranesp 18/8/2005 PFS 100mcg Darbepoetin alfa Adatco Aen 5 Abilify 15 19/9/2005 tab 15 Aripiprazole Orient Bristol Myers 6 Norprolac 75mcg 19/9/2005 tab 75mcg Quinagolide Petra drug store Ferring GmbH 7 27/11/2005 Lab 3 M Aldara 5% cream 5% imiquimod Khraim drug Store Santé/France 8 23/11/2005 Gemifloxacin Factive tab 320 mesylate Hikma Hikma 9 15/12/2005 Solifenacin Vesicare tab 10 succinate Ibn rushd Yamanoushi 10 Mycamine 10/5/2005 Vial 50 Micafungin sodium Hikma Hikma 11 3/1/2006 Eye drops Relestat solution 0.05% Epinastine Arab & Agricultura Allergen 12 Strattera 5 /2/ 2006 cap Atomoxetine Arab Drug store Eli Lilly 13 Protelos 12 /2/ 2006 powder 2gm Strontium Ranelate Jordan Les lab servier 14 Certican 19 /2/ 2006 tab 1 Everolimus Jordan Novartis pharma 15 Xoliar 21/3/2006 Inj Omalizumab Jordan Novartis pharma 16 Lyrica 5 /4/ 2006 cap 25 Pregabalin Alsabbagh Pfizer 17 9 /5/ 2006 Powder for conc Alimta for sol for infusion 25/ml Pemetrexed Arab Drug store Eli Lilly /5/ 2006 Sol for inj in Apidra vial 100IU/ml Insulin glulisine Ulfa Aventis Pharma
2 19 Levemir penfill 5 /6/ 2006 Sol for inj 100IU/ml Insulin detemir Khoury NovoNnordisk 20 Exjade 20 /6/ 2006 Dispersible tab 250 deferasirox Jordan Novartis pharma /7/ 2006 Methylphenidate ncerta tab 36 HCl Ninos Janssen cilag /8/ 2006 nc for sol for Mabcampath infusion 30/ml Alemtuzumab Jordan drug store Schering AG 23 19/12/2006 nc for sol for Aldurazyme infusion 100IU/ml laronidase الزراعية Genzyme /1/ 2007 Duloxetine Hcl 60 Eli Lilly Export Cymbalta CAP 60 The Arab S.A /1/ 2007 Oxcarbazepine 60 Trileptal tab 300 /ml 26 Baraclude tab 18 /1/ 2007 tab 1 Entecavir Orient 27 Meiact tab 14 /2/ 2007 Tab 200 Cefditoren Sukhtian Tabuk 28 Zymar 28 /3/ 2007 Opth. solu 0.3% Gatifloxacin الزراعية Allergen /7/ 2007 Les Laboratories Procoralan TAB 5 Ivabradine 5 Servier /8/ 2007 Carbetocin 100 Pabal INJE 100 ug/ml ug/ml Petra Ferring GmbH /9/ %,40 Timolol 0.50 %, Duotrav EAR Drop ug Travaprost 40 Modern Alcon-uvreur 32 2 /10/ 2007 Ranibizumab 10 Lucentis SOLU 10 /ml /ml 33 Champix /10/ 2007 TAB 0.5 Varenicline 0.5 Sabbagh Pfizer 34 18/11/ 2007 Telbivudine 600 Sebivo TAB /2/ 2008 Loteprednol Bausch & Lomb Lotemax SUSP 0.5 % Etabonate 0.5 % Petra Incorporated
3 36 28 /2/ 2008 Cladribine 10 Litak VIAL 10 /5ml /5ml Al Wafi Lipomed AG /3/ 2008 Meropenem Meronem 1gm inj 1 gm Trihydrate 1 gm AstraZeneca 38 Invega Extended Release 9 /4/ 2008 TAB 6 Paliperidone 6 Telegraph Janssen Cilag /4/ 2008 ORIENT DRUG Bristol Myers Sprycel 20 TAB 20 Dasatinib 20 STORE CO Squibb /4/ 2008 Mitiglinide Glufast TAB 5 Calcium Hydrate5 Hikma Pharmaceuticals Hikma Pharmaceuticals /5/ 2008 Suleiman Tannous & Relenza tab 5 Zanamivir 5 Sons. Ltd GSK /5/ 2008 Levobupicacaine Walid Al Turk Drug Chirocaine Amp Amp 2.5 /ml Hcl 2.5/ml Store Abbott /7/ 2008 Memantine Hcl 10 Abu Sharef Medical H-Lundbeck A/S Ebixa TAB 10 Stors overseas 44 4 /8/ /15m Natalizumab 300 Tysabri SOLU l /15ml Adatco Elan Pharma /8/ 2008 Adefovir Dipivoxil Suleiman Tannous & Hepsera TAB Sons. Ltd GlaxoWellcome 46 2 /9/ 2008 Sorafenib Tosyllate Nexavar TAB Khoury Bayer AG /11/ 2008 Gadoversetamide g/ml Optimark 0.5mmol/ml(20ml) INJE /ml Sabbagh Mallinckrodt /11/ Tasigna Cubicin 14 /12/ 2008 CAPS 200 Nilotinib 200 Daptomycin 350 Powder 350 Roche Pharma novartis
4 50 24 /12/ 2008 Rasilez tab TAB 300 Aliskiren 300 novartis 51 Januvia 31 /12/ 2008 TAB 100 Sitagliptin 100 Adatco Merck &.Inc /1/ 2009 Valganciclovir 450 F.Hoffmann La- Valcyte F.C.Tablet TAB 450 Roche 53 8 /4/ 2009 Tarceva F.C.Tablet TAB 100 Erlotinib 100 roche 54 5 /5/ 2009 Suleiman Tannous & Tykerb TAB 250 Lapatinib 250 Sons. Ltd Glaxo Group Ltd 55 7 /12/ 2009 Rivaroxaban Xarelto TAB 10 Micronized 10 Khoury Bayer Health Care 56 Firmagon vial 20/6/2010 Powder& solvent for Degarelix solution for inj 80 Petra drug store Ferring 28/11/2010 Solution for Sugammadex 57 Bridion injection 100/ml Adatco N.V Organon 10/2/2011 Jordan 58 Valdoxan Agomelatine. tab 25 Servier 59 13/11/2011 capsules Jordan Onbrez Breezhaler containing a powder for 150 and 300 Indacaterol maleate Novartis inhalation micrograms 60 Victoza 28/11/2011 Solution for inj in PFP 6 /ml Liraglutide Khoury Novo Nordisk
5 61 62 Multaq F.C tab IBD: 31/7/2009 Submission date:14/10/2010 Prolia. IBD: 26/5/2010 Submission date:16/12/ Onglyza IBD: 31/7/2009 Submission date:27/1/ /6/2012 4/3/2012 F.C tab Solution for inj in PFP /ml 17/5/2012 Tab 5 Dronedarone Denosumab Saxagliptin Ulfa Adatco drug store Sanofi Aventis Aen Astrazeneca Gilenya 64 IBD: 17/8/2010 Submission date:28/4/ Brilinta IBD: 3/12/2010 Submission date:12/5/2011 Jevtana vial 66 IBD: 17/8/2010 Submission date:28/4/ Zytiga IBD: 28/4/2011 Submission date:26/1/ Brinavess IBD: 9/2010 Submission date:27/10/ /4/ /7/ /1/ /11/ /3/2013 Cap 0.5 Fingolimod Tab 90 Ticagrelor Novartis Astrazeneca conc. & solvent for infusion. 60 Cabazitaxel Ulfa Sanofi Tablet 250 Abitraterone Acetate Telegraph Janssen-Cilag Inernational ncentrate for Solution for infusion 20/ml Vernakalant Hcl Adatco drug store MSD LTD
6 69 Trajenta IBD: 20/5/2011 Submission date: 6/11/ Incivo IBD: 23/5/2011 Submission date:13/3/ Victrelis IBD : 13/5/2011 Submission date : 19/2/ Stivarga IBD : 27/9/2012 Submission date : 14/8/2013 mmission decision date : 2/4/ Eylea IBD : 18/11/2011 Submission date : 4/4/2013 mmission decision date : 21/5/ Signifor IBD : 24/4/2012 Submission date : 20/5/2013 mmission decision date : 5/11/2014 9/10/ /10/ /7/ /5/2014 6/7/2014 8/2/2015 tablet 5 Linagliptin Arab drug store (shqer) tablet 375 Telaprevir Ninos drug store Hard capsule 200 Boceprevir Adatco drug store tablet 40 Regorafinib Khori drug store Solution for injection 40 /ml aflibercept Khori drug store Solution for injection 0.3 /ml 0.6 /ml 0.9/ml Pasireotide Dispartate Boehringer Ingelheim International GmbH,Ingelheim am Rhein Janssen-Cilag international MSD/Ltd UK Bayer Pharma A G / Germany Bayer Pharma A G / Germany /Switzerland
7 75 Zelboraf IBD : 17/8/2011 Submission date : 14/10/2012 mmission decision date : 19/11/ Lyxumia IBD : 7/1/2013 Submission Date : 28/11/2013 mmission decision date : 5/8/ Exviera IBD : 15/1/2015 Submission Date : 10/2/2015 mmission decision date : 12/8/ Viekirax IBD : 15/1/2015 Submission Date : 10/2/2015 mmission decision date : 19/8/ Giotrif IBD : 2/7/2013 Submission Date : 29/9/2014 mmission decision date : 16/9/2015 4/2/2015 9/12/ /8/ /9/ /11/2015 tablet 240 Vemurafenib Pre-filled Pen 10mcg 20mcg 10&20 mcg Lixisenatide Ulfa Tablet 250 Dasabuvir Tablet Ombitasvir Paritaprevir Ritonavir tablet 20 Afatinib Abu sheikha drug store Abu sheikha drug store Arab drug store (shqer) F.hoffman la-roche /Switzerland Sanofi avemtis groupe/ France Abbvie limited / UK Abbvie limited / UK Boehringer ingelheim international / Germany Last reviewed in 12/12015 في حال الحاجة لالعتراض على محتويات القائمة ارجو ارسال كتاب رسمي لقسم التسجيل.
New chemical Entity Registered ( )
N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Drug Store Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib
More informationNew chemical Entity Registered ( )
N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib mina
More informationTABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationNew Exception Status Benefits
AUGUST 2017 Nova Scotia Formulary Updates New Exception Status Benefits Forxiga (dapagliflozin) Xigduo (dapagliflozin and metformin hydrochloride) Criteria Update: Antipsychotic Medications Abilify (aripiprazole)
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16
New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended
More informationPORTFOLIO MADE WITH CARE. FDF Generics Chlorhexidine API
PORTFOLIO MADE WITH CARE FDF Generics Chlorhexidine API MADE WITH CARE Generics API LONG-TERM WORLDWIDE EXPERIENCE FDF HPAPI Intermediates API SEAMLESS DEVELOPMENT FDF FIRST TO MARKET GENERICS FDF MOLECULE
More informationIraq NDI Iraq 04-J India 05-AH France Famar Lyon France 05-D UNITED ARAB EMIRATES. Iraqi Biocon Limited Indian 06-AA0-001
nam origmanufacturer nammanufacturer National code Mousel Scientific Iraq NDI Iraq 04-J00-042 Sandoz GmbH Austria for Sandoz GmbH by Sandoz Ilac Sanayi ve India 05-AH0-040 France Famar Lyon France 05-D00-024
More informationApplications received for new investments since 1 November 2008
Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC s website, in accordance with the Terms of Reference for the Pharmacology
More informationCONTACT POLPHARMA GROUP POLPHARMA B2B
DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationPRAC recommendations on signals
18 May 2017 EMA/PRAC/252869/2017 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 2-5 May 2017 PRAC meeting This document provides an overview of the recommendations adopted by the Pharmacovigilance
More information2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
More informationNICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationQuality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
More informationDeaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16
New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationDrugs in Focus The early bird catches the worm! Selection of novel, still patented APIs for development activities in patent free countries
Drugs in Focus The early bird catches the worm! Selection of novel, still patented APIs for development activities in patent free countries Searching for patent circumventing manufacturing processes, polymorphic
More informationJuly 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend. Drug Type and Use. Drug Name, form(s), strength(s), Sponsor,
July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend Drug Name, form(s), ABIRATERONE, tablet, 250 mg, Zytiga Janssen-Cilag Pty Ltd Change to listing Prostate Cancer Section 85 Authority required
More informationAVAILABLE DOSSIERS. Product name Pharmaceutical form Strength Reference Therapeutic class
DOSSIER LIST AVAILABLE DOSSIERS Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM Esomeprazole sodium Omeprazole sodium injection / 40 mg Nexium / AstraZeneca
More informationLegal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS
Legal Supplement Part B Vol. 57, No. 6 18th January, 2018 11 LEGAL NOTICE NO. 5 REPUBLIC OF TRINIDAD AND TOBAGO FOOD AND DRUGS ACT, CHAP. 30:01 NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS ISSUED
More informationPRAC recommendations on signals
14 December 2017 EMA/PRAC/610978/2017 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 27-30 November 2017 PRAC meeting This document provides an overview of the recommendations adopted
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationPharmaceuticals and Medical Devices. Safety Information
Safety Information No. 243 January 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 193) 3 Flurbiprofen (oral dosage form) and 6 others 2. List of products subject to Early Post-marketing Phase Vigilance
More informationDOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST AVAILABLE DOSSIERS THERAPEUTIC CLASS / MAIN INDICATION LACTOSE FREE ZONE IV CPP FEASIBILITY ALIMENTARY TRACT & METABOLISM 1. Esomeprazole
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationMedicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationOur Values. Quality Intelligent efforts in everyday practice. Innovation Change that unlocks new value. Performance Passion for results
Product Guide Our Values 1 Innovation Change that unlocks new value Our continuous progress and growth depends on the investments we make on scientific research for new medicines and technologies. Innovation
More informationANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
22 July 2011 EMA/CHMP/557552/2011 corr* 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2011 Positive opinions for new medicines
More informationPharmaceuticals and Medical Devices. Safety Information
Safety Information No. 244 February 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 194) GEM-Premier 3000 PAK and 10 others 3 2. List of products subject to Early Post-marketing Phase Vigilance
More informationPRAC recommendations on signals
5 November 2013 EMA/PRAC/625262/2013 Pharmacovigilance Risk Assessment Committee Adopted at the PRAC meeting of 7-10 October 2013 This document provides an overview of the recommendations adopted by the
More informationMABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
More informationCRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.
ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationThis article is a CME/CE certified activity. To earn credit for this activity visit:
Novel Perspectives on Type 2 Diabetes: Traditional and Emerging Therapies and the Potential Role of the Kidneys This article is a CME/CE certified activity. To earn credit for this activity visit: www.medscape.org/lecture/t2dm-therapies
More informationOfficial Journal of the European Union C 401/3
28.12.2012 Official Journal of the European Union C 401/3 Summary of European Union s on marketing authorisations in respect of medicinal s from 1 November 2012 to 30 November 2012 (Published pursuant
More informationName of firm/applicant
Recommendation:- The 18 th Subject Expert Committee (Oncology & Hematology) deliberated the proposals on 04.07.2014 and recommended the following:- Agenda no. Drug name Name of firm/applicant Recommendations
More informationDrugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC
Area Drug and Therapeutics Committee Prescribing Supplement No 62 In this issue Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationSUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
More informationLIST OF DRUGS DURING 2004
LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004
More informationApril 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name
April 2015 May 2015 RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date Advice Published aclidinium / formoterol fumarate dehydrate (Duaklir Genuair) Almirall
More informationSUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
More informationNEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)
HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir 02357593 HIV
More informationHow Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude
More information1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000
ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More informationOregon Health Plan prescription benefit updates
Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save
More informationPRAC recommendations on signals
15 September 2016 EMA/PRAC/551805/2016 Corr 1 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the PRAC meeting of 30 August-2 September 2016 This document provides an overview of the recommendations
More informationPrescription benefit updates Large group
Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hwang TJ, Bourgeois FT, Seeger JD. Drug safety in the digital
More informationPharmaceuticals and Medical Devices Safety Information
Pharmaceuticals and Medical Devices Safety Information No. 248 July 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 198) (1) Bepridil Hydrochloride (and 1 other) 3 2. List of products subject to
More informationRecurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 Recurrent Glioblastoma Multiforme (GBM) - Pipeline
More informationTable 1. New drugs approved by the US Food and Drug Administration (FDA): December 13, 2014 through January 18, 2015
Hosp Pharm 2015;50(3):238 242 2015 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5003-238 Current FDA-Related Drug Information Approvals, Submission, and Important Labeling Changes
More informationHow to Fight Diabetes and Win. Diabetes. Medications
How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to
More informationBrand companies identified in CPS or whether generic versions are available
Appendix 3: Guideline-level data on recommended drugs and guideline-affiliated organizations Clinical practice guideline ID # Most recent review or publish date CPS year 5 2013 2013 7 2013 2013 18 2013
More informationCountry of Supplying Company. Supplying Company. Anfarm Hellas S.A. Greece
01-AA0-006 01-B00-016 Digoxin 250 mcg/ml inj (2ml) Ampoule Spironolactone 25mg Digoxin/Anfar m Spironoam 25 tab Greece Greece 6 8322 4.5 $ Iraq 10 89122 500 ID سامراء Iraq سامراء 02-B00-008 Hyocine butylbromide
More informationMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
25 June 2010 corr. 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2010 Positive opinions for new medicines adopted The Committee
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationREGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017
CHAIR John Petrie, Professor of Diabetic Medicine Financial Non-financial Non-personal Last updated Specific Non-Specific Specific Non- Specific Professor of Diabetic Medicine, University of Glasgow Academic.
More informationNIT165 - RECEIVED PRICE DETAIL. Quantity in Unit/SKU. Company Name. Abbott Healthcare Private Ltd.
S C I Total 1 120003 Acenocoumarol/Nicoumalone Tablet 2 mg 10 x 10 15,000 223.33 6 6 26.7996 250.1296 2 120016 Amitriptyle Tab. IP - 25 mg 10X10 4,120 Micron Pharmaceuticals 27.9 12 3.348 31.248 3 120030
More informationNATIVA GROUP. Inspired by Innovation and Technology
NATIVA GROUP Inspired by Innovation and Technology INNOVATION & TECHNOLOGY IS OUR PASSION Nativa is a leading group of pharmaceutical companies in Russia. It develops and produces worldclass complex medicines
More informationAetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All
More informationStatus of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016
1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationInnovative Products Available. OTC Products Available
Innovative Products Benfotiamine film-coated tablets 150 mg Cholecalciferol film-coated tablets 22400 I.U. Diltiazem rectal ointment 2% Agents for Treatment of Hemorrhoids and Fissures Blood and Blood
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationTN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018
1 Tennessee CoverRx List Run : 04/26/18 Dosage Form amiodarone HCl 200 MG TABLET ORAL 04/25/2018 0.16102 0.14405 11.8 hydralazine HCl 100 MG TABLET ORAL 04/25/2015 0.11390 0.10854 4.9 hydralazine HCl 25
More informationOrphanet Rep rts Series
List of marketing authorised Orphan Drugs in Europe January 2008 Orphan drugs by tradename in alphabetical order Orphan drugs by decreasing of marketing authorisation Orphan drugs in therapeutic areas
More informationMEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 22 June 2008
Area Drug and Therapeutics Committee Prescribing Supplement No 22 In this issue Drugs currently being considered by SMC advice due on 09 ADTC decisions carried over from the previous bulletin in February
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationGOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$2.00 WINDHOEK - 3 June 2011 No. 4726
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$2.00 WINDHOEK - 3 June 2011 No. 4726 CONTENTS Page GOVERNMENT NOTICE No. 71 Medicines and Related Substances Control Act, 2003: Registration of certain medicines...
More informationWellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/03/2015.
More informationCHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationin patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 07/3.1.2.2/23 NOVARTIS SA
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More information2018 CareOregon Advantage Part D Formulary Changes
2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD
More information